– The focus on the safety and effectiveness of insulin administration in the home care environment has shaped new product development pathways, prevailing the key stimulant of diabetes for R&D
– Parenteral delivery systems are gaining traction in a wide range of diseases, pushing the need to promote delivery success
Injection pens have become the standard of care for self-administered insulin therapy for both type 1 and type 2 diabetes. The trend has been a major lever in the evolution of the infusion pen market worldwide. Ease of use, patient friendliness, safety in dosing adjustment, among others, are some of the key anchors for the wide preference between patients and doctors. Advances in all basic design elements have led to access to infusion pens with remarkable functionality and usability of the device, not only in the delivery of insulin but also in other drugs. Thus, the injection pen market has seen a number of injection pens for parenteral administration of MAB preparations, hormones, peptides and proteins to meet the needs of patients with rheumatoid arthritis.
Delivery device technologies have come a long way, expanding the horizon for revenue generation. Earning a mediocre CAGR over the 2020-2028 forecast period, the pen market is expected to reach a valuation of US $ 6 billion by the end of the period
Free reference + All related graphs and graphs (including COVID19 impact analysis) : – https://bit.ly/3hf5PJf
Basic findings of the Injectable Pen Market Study
· Success Insulin Pen Delivery Key Focus on Diabetes Care
Injection pens have gained a striking preference over manual vials and syringes among patients requiring routine intramuscular and subcutaneous injections. Their use in the supply of insulin has become widely accepted among diabetics for proper metabolic control. Industry players with market share in the insulin pen market are increasingly leveraging the growing adoption of insulin therapy practices to improve the level of care. The attitude of patients to the use of insulin for various other chronic diseases has advanced significantly, in parallel with the continuous developments in the techniques used. In conjunction with this, governments in Europe and the United Kingdom support the adoption of home devices for the management of chronic diseases,
· Global health emergencies caused by diabetes mellitus
Diabetes is considered a global emergency of the current century, with a high prevalence among older adults. Many of these have to do with deadly medical problems that are vulnerable to diabetics because of the high risk of developing infection. According to a finding published in an article in the NCBI, in the US alone, the percentage of the population with diabetes is projected to increase by 54% from 2015 to 2028. Thus, there is a growing need to update treatment management practices with diabetes developed as well as developing world to fight morbidity. The focus is expected to push R&D into the injection pen market.
· The manufacturers are aiming at multiple design elements for innovation
Over the years, design developments in injection pens have included needle and bevel design, needle length selection by the patient, and a number of aspects of needle-tissue interactions. Continuous focus from medical companies to improve usability, accuracy and ways of developing products in the form of a recommendation.
Buying spray pens: Key drivers and avenues
· Raising awareness of the benefits of insulin in diabetes management in the developing world by boosting demand
The high prevalence of diabetes is a key growth factor
Buying injection pens: Key players
Medical device manufacturers and leading pharmaceutical companies active in the injection pen market rely on extensive evaluations of all key design parameters. They were willing to meet the various regulatory parameters to expedite approvals. Several players have benefited from growing awareness of the safety and effectiveness of their products.
Some of the players who are well connected in the infusion pen market are Becton, Dickinson and Company, AstraZeneca, Haselmeier, Owen Mumford, Sanofi, F. Hoffman-La Roche and Eli Lilly Company.
Free reference + All related graphs and graphs (including COVID19 impact analysis): – https://bit.ly/3hf5PJf